S 1391 · 116th Congress 2019โ€“2021, ended

Fair Accountability and Innovative Research Drug Pricing Act of 2019

Latest action · May 9, 2019 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMay 9, 2019
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Fair Accountability and Innovative Research Drug Pricing Act of 2019

This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.

Cosponsors 7

Members who signed on, in the order they did. Signatures ran from May 9, 2019 to Sep 19, 2019; 3 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
R-AKLisa MurkowskiOriginalMay 9, 2019
R-INMike BraunOriginalMay 9, 2019
D-MNTina SmithOriginalMay 9, 2019
I-MEAngus S. King Jr.Aug 1, 2019
R-NDJohn HoevenAug 1, 2019
R-NDKevin CramerSep 9, 2019
D-OHSherrod BrownSep 19, 2019

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred May 9, 2019

Actions 2

Everything that happened, newest first.

  1. May 9, 2019Introduced in Senate
  2. May 9, 2019Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Printed hearings 1

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
S. Hrg. 116-556LOWER HEALTH CARE COSTS ACT136 pagesHealth, Education, Labor, and Pensions CommitteeJun 18, 2019

CRS reports 2

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 2

Products on other subjects that cite it, usually among other measures.

Related bills 4

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 898Fair Accountability and Innovative Research Drug Pricing Act of 2021Reintroduced BillMar 23, 2021
S 1131Fair Accountability and Innovative Research Drug Pricing Act of 2017Reintroduction ofMay 16, 2017
S 1895Lower Health Care Costs ActRelated billJul 8, 2019
HR 2296More Efficient Tools to Realize Information for Consumers ActRelated billSep 24, 2019

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to require reporting regarding certain drug price increases, and for other purposes.
Short Title(s) as Introduced
Fair Accountability and Innovative Research Drug Pricing Act of 2019

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. May 9, 2019Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.